Monday June 26th 2017

Posts Tagged ‘ccsvi’

Going abroad for Lemtrada for MS is reminiscent of CCSVI

Going abroad for Lemtrada for MS is reminiscent of CCSVI

There are many who suffer from multiple sclerosis (MS) in the United States who are upset with the FDA for not approving of the drug Alemtuzumab, otherwise known as Lemtrada. To the point where a petition was made to fight the ruling. This, on top of Genzyme appealing the [Read More]

CCSVI 2013: ‘debunking,’ spin, and legal drama

CCSVI 2013: ‘debunking,’ spin, and legal drama

If there were a drinking game that called for taking a shot whenever the term chronic cerebrospinal venous insufficiency—or CCSVI—appeared in 2013 in a headline alongside “debunked” or “death knell,” we all would have been plastered well before New Year’s Eve. [Read More]

Wolfville couple adamant Liberation treatment offers hope

Wolfville couple adamant Liberation treatment offers hope

Wolfville area resident Christopher Alkenbrack makes no bones about it. While scientists argue about the success of the so-called Liberation therapy for Multiple Sclerosis, Alkenbrack passionately promotes what worked for him. Alkenbrack is the president of the National [Read More]

 Page 1 of 243  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]